Quotes 5-day view Delayed Nasdaq
09/25/2020
09/28/2020
09/29/2020
09/30/2020
10/01/2020
Date
299.89(c)
305.46(c)
305.5(c)
309.08(c)
309.61 Last
4 336 929
1 907 450
1 611 186
1 575 999
1 783 586 Volume
+4.74% +1.86% +0.01% +1.17% +0.17% Change
Sales 2020
3 091 M - -
Net income 2020
557 M - -
Net cash position 2020
2 294 M - -
P/E ratio 2020
84,5x
Yield 2020
-
Sales 2021
3 963 M - -
Net income 2021
946 M - -
Net cash position 2021
2 696 M - -
P/E ratio 2021
49,0x
Yield 2021
-
Capitalization
45 237 M 45 237 M -
EV / Sales 2020
13,9x
EV / Sales 2021
10,7x
Nbr of Employees
7 700
Free-Float
75,1%
Illumina, Inc. specializes in the development, manufacturing and marketing of integrated systems for the analysis of genetic variation and biological function. The group's products are for genomic research centers, pharmaceutical companies, university institutions, clinical research organizations, and biotechnology companies. Net sales break down by source of income as follows:
- product sales (82.7%): tools and...
Notations Surperformance© of Illumina, Inc.
Trading Rating : Investor Rating :
All news about ILLUMINA, INC.
News in other languages on ILLUMINA, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends ILLUMINA, INC.
Short Term Mid-Term Long Term Trends Bearish Neutral Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
HOLD
Number of Analysts
18
Average target price
302,71 $
Last Close Price
309,08 $
Spread / Highest target
22,9%
Spread / Average Target
-2,06%
Spread / Lowest Target
-28,8%
Please enable JavaScript in your browser's settings to use dynamic charts.
United Kingdom
Canada
France
Deutschland
Schweiz (DE)
Report
